Company news
Theralase Technologies Inc. news in 2024
Theralase Technologies Inc.'s news releases, calls and decks from 2024, newest first.
Theralase(R) Launches Three New Clinical Study Sites in USA
December 9, 2024
Theralase(R) Launches New Clinical Study Site in Canada
December 5, 2024
Theralase(R) Release's 3Q2024 Financial Statements
November 27, 2024
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
September 24, 2024
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
September 3, 2024
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
August 28, 2024
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
August 21, 2024
Theralase(R) Release's 2Q2024 Financial Statements
August 12, 2024
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
July 8, 2024
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
June 20, 2024
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
June 19, 2024
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
June 18, 2024
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
June 14, 2024
Rutherrin(R) Increases Efficacy of Chemotherapy
June 12, 2024
Ruvidar(TM) Enhances Efficacy of Cancer Drug
June 10, 2024
Theralase(R) Successfully Destroys Lung Cancer
June 6, 2024
Theralase(R) Technology Effective in Virus Inactivation
June 4, 2024
Theralase(R) Release's 1Q2024 Financial Statements
May 30, 2024
Theralase(R) Expands Clinical Team
May 2, 2024
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 5, 2024
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
March 26, 2024
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
February 12, 2024
Theralase Technologies shares update on Phase II Bladder Cancer study
February 8, 2024
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
February 8, 2024
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 5, 2024
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
January 15, 2024
Decks in 2024
- Investor Presentation (October 2024)
Investor deck · 26 slides · Oct 15, 2024
- Fact Sheet (October 2024)
Fact sheet · 2 slides · October 2024
- Investor Presentation (March 2024)
Investor deck · 24 slides · Mar 18, 2024